Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
OPGEN INC (OPGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
10/11/2023 8-K Quarterly results
08/10/2023 8-K Quarterly results
Docs: "OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/05/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "STANDSTILL AGREEMENT"
06/30/2023 8-K Financial Statements and Exhibits  Interactive Data
06/09/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
06/07/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/15/2023 8-K Quarterly results
Docs: "OpGen Reports First Quarter 2023 Financial Results and Provides Business Update"
05/04/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
03/14/2023 8-K Changes in Registrant's Certifying Accountant  Interactive Data
01/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
01/20/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from CohnReznick regarding change in certifying accountant"
01/18/2023 8-K Quarterly results
01/11/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "OpGen Announces Pricing of $7.5 Million Public Offering ROCKVILLE, MD., January 6, 2023 – OpGen, Inc. , a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the pricing of a public offering of an aggregate of 2,586,207 shares of its common stock , Series A-1 warrants to purchase up to 2,586,207 shares of common stock and Series A-2 warrants to purchase 2,586,207 shares of common stock, at a combined public offering price of $2.90 per share and accompanying warrants. The Series A-1 warrants will have an exercise price of $2.65 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series A-2 warrants will have an exercise price of $2.65 ...",
"OpGen Announces Closing of $7.5 Million Public Offering ROCKVILLE, MD., January 11, 2023 – OpGen, Inc. , a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced public offering of an aggregate of 2,586,207 shares of its common stock , Series A-1 warrants to purchase up to 2,586,207 shares of common stock and Series A-2 warrants to purchase 2,586,207 shares of common stock, at a combined public offering price of $2.90 per share and accompanying warrants. The Series A-1 warrants have an exercise price of $2.65 per share, are exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series A-2 warrants have an exercise price..."
01/04/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "OpGen Announced 1-for-20 Reverse Stock Split"
12/13/2022 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/03/2022 8-K Quarterly results
09/20/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform"
08/31/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement"
08/11/2022 8-K Quarterly results
07/08/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "OpGen’ s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment"
03/29/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update"
03/03/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K"
12/08/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy